Cepheid (NASDAQ:CPHD) Receives a Downgrade
Wells Fargo cut shares of Cepheid (NASDAQ:CPHD) stock from a Outperform rating to a Market Perform rating in analysts note issued on 2 December.
From a total of 16 analysts covering Cepheid (NASDAQ:CPHD) stock, 11 rate it a ”Buy”, 0 a “Sell”, and 10 a ”Hold”. This means that 52% of the ratings are positive. The highest target price is $62 while the lowest target price is $32.5. The mean of all analyst targets is $42.41 with a 25.68% above today’s ($33.06) stock price. Cepheid was the topic of 24 analyst reports since July 24, 2015 according to the firm StockzIntelligence Inc. Stifel Nicolaus initiated shares on November 12 with “Buy” rating. Needham maintained shares with “Buy” rating and $47 target share price in a report from an October 14. Canaccord Genuity downgraded CPHD stock in a recent report from October 21 to “Hold” rating. Finally, Raymond James downgraded the stock to “Mkt Perform” rating in a report issued on an October 14.
Approximately 485,630 shares of stock traded hands. Cepheid (NASDAQ:CPHD) has declined 37.91% since April 29, 2015 and is downtrending. It has underperformed by 37.71% the S&P500.
Cepheid is a molecular diagnostics company. The company has a market cap of $2.51 billion. The Firm develops, makes and markets fully-integrated systems for testing in the clinical market and non-clinical markets. It currently has negative earnings. The Company’s systems enable molecular testing for organisms and genetic diseases.
According to Zacks Investment Research, “Cepheid, Inc. develops, manufactures and markets microfluidic systems that integrate, automate and accelerate biological testing. Their systems are miniaturized instruments that analyze complex biological samples in a disposable cartridge by combining molecular biology with microfluidic technology that processes small quantities of liquid, typically using components fabricated with computer chip technology. These systems rapidly perform all of the steps required to analyze complex biological samples.” Get a free copy of the Zacks research report on Cepheid (CPHD).